Latest news with #PharmaResearch
Yahoo
28-05-2025
- Business
- Yahoo
Asian Value Stocks Priced Below Estimated Intrinsic Values
As global markets face volatility due to renewed tariff threats and shifting economic policies, investors are increasingly turning their attention to Asia, where opportunities for value investing remain robust. In this environment, identifying stocks priced below their estimated intrinsic values can be a strategic approach for those seeking potential long-term growth in the Asian market. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.23 CN¥28.32 49.8% Xiamen Amoytop Biotech (SHSE:688278) CN¥77.56 CN¥153.79 49.6% Fuji (TSE:6134) ¥2247.00 ¥4481.26 49.9% H.U. Group Holdings (TSE:4544) ¥3062.00 ¥6058.85 49.5% Shenzhen Yinghe Technology (SZSE:300457) CN¥17.28 CN¥34.50 49.9% Devsisters (KOSDAQ:A194480) ₩38500.00 ₩76148.72 49.4% TLB (KOSDAQ:A356860) ₩17600.00 ₩34842.86 49.5% Heartland Group Holdings (NZSE:HGH) NZ$0.80 NZ$1.58 49.3% BalnibarbiLtd (TSE:3418) ¥1162.00 ¥2310.67 49.7% J&T Global Express (SEHK:1519) HK$6.65 HK$13.21 49.7% Click here to see the full list of 307 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea, with a market cap of ₩4.66 trillion. Operations: PharmaResearch Co., Ltd. focuses on biopharmaceutical operations primarily within South Korea. Estimated Discount To Fair Value: 24.7% PharmaResearch is trading at approximately 24.7% below its estimated fair value of ₩596,088.91, with a current price of ₩449,000. The company's earnings are forecast to grow significantly at 25.85% annually over the next three years, outpacing the Korean market average of 20.5%. Revenue growth is also expected to be robust at 24.4% per year, surpassing the market's 7.4%, highlighting its potential as an undervalued cash flow opportunity in Asia. Our comprehensive growth report raises the possibility that PharmaResearch is poised for substantial financial growth. Take a closer look at PharmaResearch's balance sheet health here in our report. Overview: Hyosung Heavy Industries Corporation manufactures and sells heavy electrical equipment both in South Korea and internationally, with a market cap of ₩5.67 trillion. Operations: Hyosung Heavy Industries generates revenue primarily through the manufacturing and sale of heavy electrical equipment domestically and abroad. Estimated Discount To Fair Value: 26.6% Hyosung Heavy Industries is trading at approximately 26.6% below its estimated fair value of ₩829,765.66, with a current price of ₩609,000. The company's earnings are projected to grow significantly at 21.94% annually over the next three years, exceeding the Korean market's growth rate of 20.5%. Although revenue growth is slower than desired at 9.8%, it still surpasses the market average of 7.4%, positioning it as an undervalued cash flow opportunity in Asia. Our growth report here indicates Hyosung Heavy Industries may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Hyosung Heavy Industries. Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩7.11 trillion. Operations: The company generates revenue primarily from its New Pharmaceutical Business segment, amounting to ₩578 billion. Estimated Discount To Fair Value: 48.4% SK Biopharmaceuticals is trading at ₩90,800, significantly below its estimated fair value of ₩176,112.28, presenting a potential undervalued cash flow opportunity. Despite earnings growth forecasted at 18% annually—slightly below the Korean market's 20.5%—revenue is expected to increase by 22.8% per year, outpacing the market average of 7.4%. The company recently became profitable and anticipates high future returns on equity at 32.5%. Upon reviewing our latest growth report, SK Biopharmaceuticals' projected financial performance appears quite optimistic. Get an in-depth perspective on SK Biopharmaceuticals' balance sheet by reading our health report here. Take a closer look at our Undervalued Asian Stocks Based On Cash Flows list of 307 companies by clicking here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A214450 KOSE:A298040 and KOSE:A326030. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
28-05-2025
- Business
- Yahoo
Asian Value Stocks Priced Below Estimated Intrinsic Values
As global markets face volatility due to renewed tariff threats and shifting economic policies, investors are increasingly turning their attention to Asia, where opportunities for value investing remain robust. In this environment, identifying stocks priced below their estimated intrinsic values can be a strategic approach for those seeking potential long-term growth in the Asian market. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.23 CN¥28.32 49.8% Xiamen Amoytop Biotech (SHSE:688278) CN¥77.56 CN¥153.79 49.6% Fuji (TSE:6134) ¥2247.00 ¥4481.26 49.9% H.U. Group Holdings (TSE:4544) ¥3062.00 ¥6058.85 49.5% Shenzhen Yinghe Technology (SZSE:300457) CN¥17.28 CN¥34.50 49.9% Devsisters (KOSDAQ:A194480) ₩38500.00 ₩76148.72 49.4% TLB (KOSDAQ:A356860) ₩17600.00 ₩34842.86 49.5% Heartland Group Holdings (NZSE:HGH) NZ$0.80 NZ$1.58 49.3% BalnibarbiLtd (TSE:3418) ¥1162.00 ¥2310.67 49.7% J&T Global Express (SEHK:1519) HK$6.65 HK$13.21 49.7% Click here to see the full list of 307 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea, with a market cap of ₩4.66 trillion. Operations: PharmaResearch Co., Ltd. focuses on biopharmaceutical operations primarily within South Korea. Estimated Discount To Fair Value: 24.7% PharmaResearch is trading at approximately 24.7% below its estimated fair value of ₩596,088.91, with a current price of ₩449,000. The company's earnings are forecast to grow significantly at 25.85% annually over the next three years, outpacing the Korean market average of 20.5%. Revenue growth is also expected to be robust at 24.4% per year, surpassing the market's 7.4%, highlighting its potential as an undervalued cash flow opportunity in Asia. Our comprehensive growth report raises the possibility that PharmaResearch is poised for substantial financial growth. Take a closer look at PharmaResearch's balance sheet health here in our report. Overview: Hyosung Heavy Industries Corporation manufactures and sells heavy electrical equipment both in South Korea and internationally, with a market cap of ₩5.67 trillion. Operations: Hyosung Heavy Industries generates revenue primarily through the manufacturing and sale of heavy electrical equipment domestically and abroad. Estimated Discount To Fair Value: 26.6% Hyosung Heavy Industries is trading at approximately 26.6% below its estimated fair value of ₩829,765.66, with a current price of ₩609,000. The company's earnings are projected to grow significantly at 21.94% annually over the next three years, exceeding the Korean market's growth rate of 20.5%. Although revenue growth is slower than desired at 9.8%, it still surpasses the market average of 7.4%, positioning it as an undervalued cash flow opportunity in Asia. Our growth report here indicates Hyosung Heavy Industries may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Hyosung Heavy Industries. Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩7.11 trillion. Operations: The company generates revenue primarily from its New Pharmaceutical Business segment, amounting to ₩578 billion. Estimated Discount To Fair Value: 48.4% SK Biopharmaceuticals is trading at ₩90,800, significantly below its estimated fair value of ₩176,112.28, presenting a potential undervalued cash flow opportunity. Despite earnings growth forecasted at 18% annually—slightly below the Korean market's 20.5%—revenue is expected to increase by 22.8% per year, outpacing the market average of 7.4%. The company recently became profitable and anticipates high future returns on equity at 32.5%. Upon reviewing our latest growth report, SK Biopharmaceuticals' projected financial performance appears quite optimistic. Get an in-depth perspective on SK Biopharmaceuticals' balance sheet by reading our health report here. Take a closer look at our Undervalued Asian Stocks Based On Cash Flows list of 307 companies by clicking here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A214450 KOSE:A298040 and KOSE:A326030. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Forbes
27-05-2025
- Business
- Forbes
Maker Of Popular Skin Booster Shot Rejuran Becomes Billionaire On K-Beauty Boom
getty The growing popularity of PharmaResearch's skin booster injection Rejuran, which is made from salmon sperm cells, has boosted shares of the biopharma company by about 230% over the past year. The stock surge has made Jung Sang-soo, the company's founder and chairman, South Korea's newest billionaire. With a 30% stake, Jung, who turned 67 in April, is the largest shareholder of PharmaResearch, which is listed on South Korea's technology-rich Kosdaq stock exchange. Forbes estimates Jung's net worth at $1.2 billion as of Tuesday's stock market close. Jung founded PharmaResearch in 2001 and listed it on the Kosdaq in 2015. He studied pharmacy at Chung-Ang University in Seoul and worked at Daewoong Pharmaceutical. Based in Gangneung, east of Seoul, PharmaResearch specializes in using PDRN (polydeoxyribonucleotide) and PN (polynucleotide) to treat wrinkles. 'PDRN and PN are regenerative medicine raw materials with proven safety and efficacy, and their composition is a DNA fragment isolated from salmon sperm cells,' PharmaResearch explained in its quarterly regulatory filing. 'As a tissue repair stimulator, PDRN's representative functions are promoting cell production and secretion of various growth factors…PN is a DNA fraction with a longer nucleic acid chain than PDRN.' Its flagship product is Rejuran, which was launched in 2014 and is sold across Asia. PharmaResearch reported that revenue rose 56% year-over-year to 117 billion won ($85 million) in the first quarter, while net income nearly doubled from the previous year to 36 billion won. About 78% of its revenue came from anti-aging products. 'While general filler procedures focus on artificial volume improvement, Rejuran is differentiated in that it induces skin cell regeneration and ECM (extracellular matrix) stability recovery by directly injecting effective ingredients into the dermis layer,' PharmaResearch said in a regulatory filing. 'This has increased its popularity among consumers who prefer natural skin improvement, and continuous effects through repeated procedures are also factors driving market demand.' Citing data from Precedence Research, PharmaResearch said in the filing the global anti-aging market is expected to grow from about $73 billion in 2024 to $140.9 billion in 2034. One reason for such galloping growth is rising awareness of self-care. Another tailwind is that Korean cosmetics and beauty devices have become wildly popular. 'Recently, interest in skin care treatments has been rapidly increasing among foreign medical tourists visiting Korea, and among these, dermatological treatment accounts for the largest proportion in the field of attracting foreign patients,' PharmaResearch said in the filing. South Korea's cosmetics exports grew 21% year-over-year in 2024 to a record $10.2 billion, according to the country's Ministry of Food and Drug Safety. The growing K-beauty craze catapulted Jung Sung-jae (no relation to PharmaResearch's founder), founder of beauty device maker Classys, into the ranks of Korea's 50 Richest list for the first time last month with an estimated fortune of $760 million. Classys' flagship product is Ultraformer MPT, a high-intensity focused ultrasound device that provides a non-invasive way to tighten and lift skin by regenerating new collagen. In 2022, Bain Capital Private Equity bought a 60% stake in Classys from Jung and his wife, Lee Yeon-joo, and their two children for 670 billion won (about $560 million at the time). Private equity giants have been circling PharmaResearch with CVC Capital, investing 200 billion won in the company last September for a 10% stake. 'It appears that the company has begun penetration into aesthetics shops in Southeast Asia by tapping into the partner CVC Capital Partners' sales network,' Shinhan Securities analysts Jung Hee-ryeong and Eom Min-yong said in a research note in November. 'Given that Southeast Asia accounts for a large portion of Rejuran exports, the medical device business is expected to see steep growth in 2025.'
Yahoo
29-04-2025
- Business
- Yahoo
Asian Stocks Trading Below Estimated Value In April 2025
As of April 2025, Asian markets are navigating a landscape marked by easing trade tensions and cautious optimism, with China and Japan showing resilience amid global economic uncertainties. In this context, identifying undervalued stocks becomes crucial for investors seeking opportunities in Asia's diverse markets, where potential value can be unlocked through careful analysis of fundamentals and market positioning. Name Current Price Fair Value (Est) Discount (Est) Xiamen Amoytop Biotech (SHSE:688278) CN¥74.29 CN¥144.77 48.7% BYD Electronic (International) (SEHK:285) HK$31.80 HK$63.03 49.5% Alexander Marine (TWSE:8478) NT$142.50 NT$280.32 49.2% Zhende Medical (SHSE:603301) CN¥19.33 CN¥37.64 48.6% Members (TSE:2130) ¥1137.00 ¥2211.77 48.6% Rakus (TSE:3923) ¥2194.50 ¥4296.95 48.9% Beijing Zhong Ke San Huan High-Tech (SZSE:000970) CN¥10.51 CN¥20.78 49.4% BalnibarbiLtd (TSE:3418) ¥1152.00 ¥2223.40 48.2% Swire Properties (SEHK:1972) HK$16.82 HK$32.75 48.6% Yuhan (KOSE:A000100) ₩113000.00 ₩219128.89 48.4% Click here to see the full list of 263 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Overview: PharmaResearch Co., Ltd., along with its subsidiaries, is a biopharmaceutical company operating mainly in South Korea, with a market capitalization of approximately ₩3.91 trillion. Operations: The company generates revenue primarily from its Pharmaceuticals segment, amounting to approximately ₩350.12 billion. Estimated Discount To Fair Value: 24.5% PharmaResearch is trading at ₩376,000, below its estimated fair value of ₩497,834.15, indicating it may be undervalued based on cash flows. The company forecasts revenue growth of 19.7% annually, surpassing the Korean market's 7.8%. Earnings are expected to grow significantly at 25% per year over the next three years. Recent dividend increases and a strong return on equity forecast further enhance its investment appeal amidst robust financial performance indicators. Our growth report here indicates PharmaResearch may be poised for an improving outlook. Unlock comprehensive insights into our analysis of PharmaResearch stock in this financial health report. Overview: Auras Technology Co., Ltd. manufactures, processes, and retails electronic materials and computer cooling modules across China, Taiwan, Ireland, Singapore, the United States, and internationally with a market cap of NT$45.67 billion. Operations: The company's revenue primarily comes from its Electronic Components & Parts segment, which generated NT$15.78 billion. Estimated Discount To Fair Value: 44.1% Auras Technology, trading at NT$506, is significantly undervalued with an estimated fair value of NT$904.98. It reported a notable earnings growth of 53.6% last year and forecasts revenue to grow at 21.4% annually, outpacing the Taiwan market's 9.5%. Earnings are expected to rise by 28.5% per year over the next three years, despite recent share price volatility, highlighting its potential as an undervalued stock based on cash flows in Asia. Our expertly prepared growth report on Auras Technology implies its future financial outlook may be stronger than recent results. Get an in-depth perspective on Auras Technology's balance sheet by reading our health report here. Overview: Aozora Bank, Ltd., along with its subsidiaries, offers a range of banking products and services both in Japan and internationally, with a market capitalization of ¥272.33 billion. Operations: Aozora Bank, Ltd. generates revenue through its diverse banking products and services offered domestically and internationally. Estimated Discount To Fair Value: 46.6% Aozora Bank is trading at ¥1,968, significantly below its estimated fair value of ¥3,685.05, highlighting its status as undervalued based on cash flows. The bank reported a turnaround with a net income of ¥16.23 billion for the nine months ending December 2024 compared to a loss previously. However, it faces challenges with high bad loans (2.1%) and past shareholder dilution but anticipates profitability growth above market averages over the next three years. Insights from our recent growth report point to a promising forecast for Aozora Bank's business outlook. Take a closer look at Aozora Bank's balance sheet health here in our report. Unlock our comprehensive list of 263 Undervalued Asian Stocks Based On Cash Flows by clicking here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A214450 TPEX:3324 and TSE:8304. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
29-04-2025
- Business
- Yahoo
Asian Stocks Trading Below Estimated Value In April 2025
As of April 2025, Asian markets are navigating a landscape marked by easing trade tensions and cautious optimism, with China and Japan showing resilience amid global economic uncertainties. In this context, identifying undervalued stocks becomes crucial for investors seeking opportunities in Asia's diverse markets, where potential value can be unlocked through careful analysis of fundamentals and market positioning. Name Current Price Fair Value (Est) Discount (Est) Xiamen Amoytop Biotech (SHSE:688278) CN¥74.29 CN¥144.77 48.7% BYD Electronic (International) (SEHK:285) HK$31.80 HK$63.03 49.5% Alexander Marine (TWSE:8478) NT$142.50 NT$280.32 49.2% Zhende Medical (SHSE:603301) CN¥19.33 CN¥37.64 48.6% Members (TSE:2130) ¥1137.00 ¥2211.77 48.6% Rakus (TSE:3923) ¥2194.50 ¥4296.95 48.9% Beijing Zhong Ke San Huan High-Tech (SZSE:000970) CN¥10.51 CN¥20.78 49.4% BalnibarbiLtd (TSE:3418) ¥1152.00 ¥2223.40 48.2% Swire Properties (SEHK:1972) HK$16.82 HK$32.75 48.6% Yuhan (KOSE:A000100) ₩113000.00 ₩219128.89 48.4% Click here to see the full list of 263 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Overview: PharmaResearch Co., Ltd., along with its subsidiaries, is a biopharmaceutical company operating mainly in South Korea, with a market capitalization of approximately ₩3.91 trillion. Operations: The company generates revenue primarily from its Pharmaceuticals segment, amounting to approximately ₩350.12 billion. Estimated Discount To Fair Value: 24.5% PharmaResearch is trading at ₩376,000, below its estimated fair value of ₩497,834.15, indicating it may be undervalued based on cash flows. The company forecasts revenue growth of 19.7% annually, surpassing the Korean market's 7.8%. Earnings are expected to grow significantly at 25% per year over the next three years. Recent dividend increases and a strong return on equity forecast further enhance its investment appeal amidst robust financial performance indicators. Our growth report here indicates PharmaResearch may be poised for an improving outlook. Unlock comprehensive insights into our analysis of PharmaResearch stock in this financial health report. Overview: Auras Technology Co., Ltd. manufactures, processes, and retails electronic materials and computer cooling modules across China, Taiwan, Ireland, Singapore, the United States, and internationally with a market cap of NT$45.67 billion. Operations: The company's revenue primarily comes from its Electronic Components & Parts segment, which generated NT$15.78 billion. Estimated Discount To Fair Value: 44.1% Auras Technology, trading at NT$506, is significantly undervalued with an estimated fair value of NT$904.98. It reported a notable earnings growth of 53.6% last year and forecasts revenue to grow at 21.4% annually, outpacing the Taiwan market's 9.5%. Earnings are expected to rise by 28.5% per year over the next three years, despite recent share price volatility, highlighting its potential as an undervalued stock based on cash flows in Asia. Our expertly prepared growth report on Auras Technology implies its future financial outlook may be stronger than recent results. Get an in-depth perspective on Auras Technology's balance sheet by reading our health report here. Overview: Aozora Bank, Ltd., along with its subsidiaries, offers a range of banking products and services both in Japan and internationally, with a market capitalization of ¥272.33 billion. Operations: Aozora Bank, Ltd. generates revenue through its diverse banking products and services offered domestically and internationally. Estimated Discount To Fair Value: 46.6% Aozora Bank is trading at ¥1,968, significantly below its estimated fair value of ¥3,685.05, highlighting its status as undervalued based on cash flows. The bank reported a turnaround with a net income of ¥16.23 billion for the nine months ending December 2024 compared to a loss previously. However, it faces challenges with high bad loans (2.1%) and past shareholder dilution but anticipates profitability growth above market averages over the next three years. Insights from our recent growth report point to a promising forecast for Aozora Bank's business outlook. Take a closer look at Aozora Bank's balance sheet health here in our report. Unlock our comprehensive list of 263 Undervalued Asian Stocks Based On Cash Flows by clicking here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A214450 TPEX:3324 and TSE:8304. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
